Nine-year outcome of ranibizumab monotherapy for choroidal neovascularization secondary to pathologic myopia
Ophthalmologica Dec 29, 2017
Pastore MR, et al. - This study was carried out to assess the 9-year outcome of ranibizumab monotherapy for myopic choroidal neovascularization (mCNV). As a result of a 9-year treatment with ranibizumab monotherapy, no change or better best-corrected visual acuity (BCVA) was noted, compared to baseline, in almost all eyes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
